Cisplatin downregulates BCL2L12, a novel apoptosis-related gene, in glioblastoma cells

详细信息    查看全文

• 作者：Mahdieh Sadat Taghavi (1)
  Azim Akbarzadeh (2)
  Reza Mahdian (3)
  Kayhan Azadmanesh (4)
  Gholamreza Javadi (1)
  
• 关键词：BCL2L12 ; Cisplatin ; Apoptosis ; Glioblastoma multiforme
• 刊名：In Vitro Cellular & Developmental Biology - Animal
• 出版年：2013
• 出版时间：June 2013
• 年：2013
• 卷：49
• 期：6
• 页码：465-472
• 全文大小：416KB
• 参考文献：1. Argyriou A. A.; Antonacopoulou A.; Iconomou G.; Kalofonos H. P. Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. / Crit. Rev. Oncol. Hematol. 69(3): 199-10; 2009. CrossRef
  2. Baldwin R. M.; Garratt-Lalonde M.; Parolin D. A.; Krzyzanowski P. M.; Andrade M. A.; Lorimer I. A. Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Ciota-mediated attenuation of p38 MAP kinase signaling. / Oncogene 25(20): 2909-919; 2006. CrossRef
  3. Boulikas T.; Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). / Oncol. Rep. 11: 559-95; 2004.
  4. Carminati P. O.; Mello S. S.; Fachin A. L.; Junta C. M.; Sandrin-Garcia P.; Carlotti C. G.; Donadi E. A.; Passos G. A.; Sakamoto-Hojo E. T. Alterations in gene expression profiles correlated with cisplatin cytotoxicity in the glioma U343 cell line. / Genet. Mol. Biol. 33(1): 159-68; 2010. CrossRef
  5. Fendri A.; Kontos C. K.; Khabir A.; Mokdad-Gargouri R.; Scorilas A. BCL2L12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. / Mol. Med. 17(3-): 163-71; 2011.
  6. Floros K. V.; Talieri M.; Scorilas A. Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. / Biol. Chem. 387(12): 1629-633; 2006a. CrossRef
  7. Floros K. V.; Thomadaki H.; Florou D.; Talieri M.; Scorilas A. Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. / Ann. N. Y. Acad. Sci. 1090: 89-7; 2006b. CrossRef
  8. Floros K. V.; Thomadaki H.; Lallas G.; Katsaros N.; Talieri M.; Scorilas A. Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. / Ann. N. Y. Acad. Sci. 1010: 153-58; 2003. CrossRef
  9. Florou D.; Papadopoulos I. N.; Scorilas A. Molecular analysis and prognostic impact of the novel apoptotic gene BCL2L12 in gastric cancer. / Biochem. Biophys. Res. Commun. 391(1): 214-18; 2010. CrossRef
  10. Furnari F. B.; Fenton T.; Bachoo R. M.; Mukasa A.; Stommel J. M.; Stegh A.; Hahn W. C.; Ligon K. L.; Louis D. N.; Brennan C.; Chin L.; DePinho R. A.; Cavenee W. K. Malignant astrocytic glioma: genetics, biology, and paths to treatment. / Genes Dev. 21(21): 2683-710; 2007. CrossRef
  11. Geomela P. A.; Kontos C. K.; Yiotakis I.; Scorilas A. Quantitative expression analysis of the apoptosis-related gene, BCL2L12, in head and neck squamous cell carcinoma. / J. Oral Pathol. Med. 42(2): 154-61; 2013. CrossRef
  12. Gonzalez V.; Fuertes M.; Alonso C.; Perez J. Is cisplatin-induced cell death always produced by apoptosis? / Mol. Pharmacol. 59(4): 657-63; 2001.
  13. Hong Y.; Yang J.; Wu W.; Wang W.; Kong X.; Wang Y.; Yun X.; Zong H.; Wei Y.; Zhang S.; Gu J. Knockdown of BCL2L12 leads to cisplatin resistance in MDA-MB-231 breast cancer cells. / Biochim. Biophys. Acta 1782(11): 649-57; 2008. CrossRef
  14. Jamieson E. R.; Lippard S. J. Structure, recognition, and processing of cisplatin-DNA adducts. / Chem. Rev. 99(9): 2467-498; 1999. CrossRef
  15. Jordan P.; Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. / Cell Mol. Life Sci. 57(8-): 1229-235; 2000. CrossRef
  16. Karan-Djurasevic T.; Palibrk V.; Zukic B.; Spasovski V.; Glumac I.; Colovic M.; Colovic N.; Jurisic V.; Scorilas A.; Pavlovic S.; Tosic N. Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. / Med. Oncol. 30(1): 405-09; 2013. CrossRef
  17. Kleihues P.; Louis D. N.; Scheithauer B. W.; Rorke L. B.; Reifenberger G.; Burger P. C.; Cavenee W. K. "The WHO classification of tumors of the nervous system. / J. Neuropathol. Exp. Neurol. 61(3): 215-25; 2002.
  18. Kontos C. K.; Papadopoulos I. N.; Scorilas A. Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene BCL2L12 in colon cancer. / Biol. Chem. 389(12): 1467-475; 2008. CrossRef
  19. Kontos C. K.; Scorilas A. Molecular cloning of novel alternatively spliced variants of BCL2L12, a new member of the BCL2 gene family, and their expression analysis in cancer cells. / Gene 505(1): 153-66; 2012. CrossRef
  20. Korbakis D.; Scorilas A. Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12. / Tumour Biol. 30(2): 100-07; 2009. CrossRef
  21. Lemaire M.; Schwartz A.; Rahmouni A.; Leng M. Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum (II) and DNA. / Proc. Natl. Acad. Sci. U. S. A. 88(5): 1982-985; 1991. CrossRef
  22. Mathioudaki K.; Scorilas A.; Papadokostopoulou A.; Xynopoulos D.; Arnogianaki N.; Agnanti N.; Talieri M. Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer. / Biol. Chem. 385(9): 779-83; 2004.
  23. Mu Q. T.; Ouyang G. F.; Lou Y. R.; Chen X. P.; Lu Y.; Liang W.; Zhang Y.; Xu W. Inducing-apoptosis effect of bortezomib on acute monocytic leukemia cell SHI-1 and its influence on expressions of Bcl2l12, Bcl-2 and Bax genes. / Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(5): 1016-020; 2008.
  24. Papageorgiou S. G.; Kontos C. K.; Pappa V.; Thomadaki H.; Kontsioti F.; Dervenoulas J.; Papageorgiou E.; Economopoulos T.; Scorilas A. The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker. / Oncologist 16(9): 1280-291; 2011. CrossRef
  25. Pinto A.; Lippard S. Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum (II). / Proc. Natl. Acad. Sci. U. S. A. 82(14): 4616-619; 1985. CrossRef
  26. Raza S. M.; Lang F. F.; Aggarwal B. B.; Fuller G. N.; Wildrick D. M.; Sawaya R. Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. / Neurosurgery 51(1): 2-2; 2002. discussion 12-. CrossRef
  27. Scorilas A.; Kyriakopoulou L.; Yousef G. M.; Ashworth L. K.; Kwamie A.; Diamandis E. P. Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. / Genomics 72(2): 217-21; 2001. CrossRef
  28. Shahbazi S.; Baniahmad F.; Zakiani-Roudsari M.; Raigani M.; Mahdian R. Nonsense mediated decay of VWF mRNA subsequent to c.7674-7675insC mutation in type3 VWD patients. / Blood Cells Mol. Dis. 49(1): 48-2; 2012. CrossRef
  29. Stegh A. H.; Brennan C.; Mahoney J. A.; Forloney K. L.; Jenq H. T.; Luciano J. P.; Protopopov A.; Chin L.; Depinho R. A. Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. / Genes Dev. 24(19): 2194-204; 2010. CrossRef
  30. Stegh A. H.; Chin L.; David N.; Louis Dn.; DePinho R. A. "What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator." Cell Cycle 7(18): 2833-839; 2008a.
  31. Stegh A. H.; Kesari S.; Mahoney J. E.; Jenq H. T.; Forloney K. L.; Protopopov A.; Louis D. N.; Chin L.; DePinho R. A. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. / Proc. Natl. Acad. Sci. U. S. A. 105(31): 10703-0708; 2008. CrossRef
  32. Stegh A. H.; Kim H.; Bachoo R. M.; Forloney K. L.; Zhang J.; Schulze H.; Park K.; Hannon G. J.; Yuan J.; Louis D. N.; DePinho R. A.; Chin L. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. / Genes Dev. 21(1): 98-11; 2007. CrossRef
  33. Taglinger K.; Van Nguyen N.; Helps C. R.; Day M. J.; Foster A. P. Quantitative real-time RT-PCR measurement of cytokine mRNA expression in the skin of normal cats and cats with allergic skin disease. / Vet. Immunol. Immunopathol. 122(3-): 216-30; 2008. CrossRef
  34. Thomadaki H.; Floros K. V.; Scorilas A. Molecular response of HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, including the new member BCL2L12. / Ann. N. Y. Acad. Sci. 1171: 276-83; 2009. CrossRef
  35. Thomadaki H.; Scorilas A. Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. / Ann. N. Y. Acad. Sci. 1095: 35-4; 2007. CrossRef
  36. Thomadaki H.; Scorilas A. Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol. / Biol. Chem. 389(11): 1427-434; 2008. CrossRef
  37. Thomadaki H.; Talieri M.; Scorilas A. Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. / Biol. Chem. 387(8): 1081-086; 2006. CrossRef
  38. Thomadaki H.; Talieri M.; Scorilas A. Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. / Cancer Lett. 247(1): 48-5; 2007. CrossRef
  39. Valente V.; Teixeira S. A.; Neder L.; Okamoto O. K.; Oba-Shinjo S. M.; Marie S. K.; Scrideli C. A.; Paco-Larson M. L.; Carlotti Jr. C. G. Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR. / BMC Mol. Biol. 10: 17; 2009. CrossRef
  40. Villani G.; Hubscher U.; Butour J. L. Sites of termination of in vitro DNA synthesis on cis-diamminedichloroplatinum(II) treated single-stranded DNA: a comparison between / E. coli DNA polymerase I and eucaryotic DNA polymerases alpha. / Nucleic Acids Res. 16(10): 4407-418; 1988. CrossRef
  41. Yao X.; Panichpisal K.; Kurtzman N.; Nugent K. Cisplatin nephrotoxicity: a review. / Am. J. Med. Sci. 334(2): 115-24; 2007. CrossRef
  42. Yatomi M.; Takiguchi Y.; Asaka-Amano Y.; Arai M.; Tada Y.; Kurosu K.; Sakao S.; Kasahara Y.; Tanabe N.; Tatsumi K.; Seki N.; Kuriyama T. Altered gene expression by cisplatin in a human squamous cell lung carcinoma cell line. / Anticancer. Res. 27(5A): 3235-243; 2007.
  43. Zhuo Z.; Zhang L.; Mu Q.; Lou Y.; Gong Z.; Shi Y.; Ouyang G.; Zhang Y. The effect of combination treatment with docosahexaenoic acid and 5-fluorouracil on the mRNA expression of apoptosis-related genes, including the novel gene BCL2L12, in gastric cancer cells. / InVitro Cell. Dev. Biol. Anim. 45(1-): 69-4; 2009. CrossRef
  44. Zinkel S.; Gross A.; Yang E. BCL2 family in DNA damage and cell cycle control. / Cell Death Differ. 13(8): 1351-359; 2006. CrossRef
  
• 作者单位：Mahdieh Sadat Taghavi (1)
  Azim Akbarzadeh (2)
  Reza Mahdian (3)
  Kayhan Azadmanesh (4)
  Gholamreza Javadi (1)
  
  1. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
  2. Pilot Biotechnology Department, Pasteur Institute of Iran, Tehran, Iran
  3. Biotechnology Research Center, Molecular Medicine Department, Pasteur Institute of Iran, Tehran, Iran
  4. Virology Department, Pasteur Institute of Iran, Tehran, Iran
  

文摘

Glioblastoma progression is mainly characterized by intense apoptosis resistance and marked necrosis. Over-expression of BCL2L12, a novel member of Bcl-2 family has been shown in primary glioblastoma. BCL2L12 blocks effective caspase-3/7 maturation and inhibits p53 tumor suppressor, deriving resistance toward apoptosis and inducing extensive cell necrosis. Cisplatin is a major chemotherapeutic agent which has a broad range of anti-neoplastic activities including apoptosis induction. To investigate the effect of cisplatin on the expression of BCL2L12 in glioblastoma cells, two glioblastoma cell lines were treated with different concentrations of cisplatin for 48?h. The cell viability and IC50 was determined using MTT assay. Then, the two glioblastoma cell lines were treated with 48?h IC50 concentration of cisplatin for 24, 48, and 72?h. Apoptosis induction was analyzed by fluorescence microscopy and flow cytometry. Gene expression study was performed on BCL2L12 and TBP as target and internal control genes, respectively. The quantitative real-time polymerase chain reaction results showed that BCL2L12 gene expression was significantly (p--.001) downregulated in the presence of cisplatin. In conclusion, cisplatin treatment induced a time-dependent apoptosis in glioblastoma cells, at least partially via downregulation of BCL2L12 gene expression.